Advertisement
Corrigendum
Open Access |
10.1172/JCI206371
Find articles by Kawai, M. in: PubMed | Google Scholar
Find articles by
Fukuda, A.
in:
PubMed
|
Google Scholar
|
Find articles by Ikeda, M. in: PubMed | Google Scholar
Find articles by Iimori, K. in: PubMed | Google Scholar
Find articles by Mizukoshi, K. in: PubMed | Google Scholar
Find articles by Iwane, K. in: PubMed | Google Scholar
Find articles by Yamakawa, G. in: PubMed | Google Scholar
Find articles by Omatsu, M. in: PubMed | Google Scholar
Find articles by
Namikawa, M.
in:
PubMed
|
Google Scholar
|
Find articles by Sono, M. in: PubMed | Google Scholar
Find articles by
Masuda, T.
in:
PubMed
|
Google Scholar
|
Find articles by Fukunaga, Y. in: PubMed | Google Scholar
Find articles by
Nagao, M.
in:
PubMed
|
Google Scholar
|
Find articles by Araki, O. in: PubMed | Google Scholar
Find articles by
Yoshikawa, T.
in:
PubMed
|
Google Scholar
|
Find articles by Ogawa, S. in: PubMed | Google Scholar
Find articles by
Hiramatsu, Y.
in:
PubMed
|
Google Scholar
|
Find articles by Tsuda, M. in: PubMed | Google Scholar
Find articles by
Maruno, T.
in:
PubMed
|
Google Scholar
|
Find articles by
Nakanishi, Y.
in:
PubMed
|
Google Scholar
|
Find articles by
Saur, D.
in:
PubMed
|
Google Scholar
|
Find articles by Tsuruyama, T. in: PubMed | Google Scholar
Find articles by
Masui, T.
in:
PubMed
|
Google Scholar
|
Find articles by
Hatano, E.
in:
PubMed
|
Google Scholar
|
Find articles by Seno, H. in: PubMed | Google Scholar
Published April 1, 2026 - More info
Mutations in Polybromo 1 (PBRM1), a subunit of the switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex, are frequently observed in several cancers, including pancreatic ductal adenocarcinoma (PDAC). In this study, we demonstrated that pancreas-specific loss of Pbrm1 in mice harboring Kras mutations and Trp53 deletions accelerated the development of poorly differentiated PDAC, epithelial-mesenchymal transition (EMT), and metastasis, resulting in worsened prognosis. Pbrm1 loss in preexisting PDAC shifted the tumor grade from a well- to a poorly differentiated state and elevated vimentin expression. Pbrm1-null PDAC exhibited downregulation of apical junction genes and upregulation of EMT pathway genes, including the vimentin and squamous molecular subtype signature genes. Mechanistically, PBRM1 bound to the vimentin gene promoter and directly downregulated its expression. Furthermore, suppression of vimentin in Pbrm1-null PDAC cells reversed the dedifferentiation phenotype and reduced EMT and metastasis. Consistently, reduced PBRM1 expression correlated with high vimentin expression, poorly differentiated histology, a high recurrence rate, and reduced overall survival in human PDACs. Additionally, PDAC with PBRM1 deletion was associated with the aggressive squamous molecular subtype. Our data established PBRM1 as a tumor suppressor that controls tumor grade and metastasis of PDAC by regulating vimentin expression.
Munenori Kawai, Akihisa Fukuda, Munehiro Ikeda, Kei Iimori, Kenta Mizukoshi, Kosuke Iwane, Go Yamakawa, Mayuki Omatsu, Mio Namikawa, Makoto Sono, Tomonori Masuda, Yuichi Fukunaga, Munemasa Nagao, Osamu Araki, Takaaki Yoshikawa, Satoshi Ogawa, Yukiko Hiramatsu, Motoyuki Tsuda, Takahisa Maruno, Yuki Nakanishi, Dieter Saur, Tatsuaki Tsuruyama, Toshihiko Masui, Etsuro Hatano, Hiroshi Seno
Original citation: J Clin Invest. 2025;135(11):e177533. https://doi.org/10.1172/JCI177533
Citation for this corrigendum: J Clin Invest. 2026;136(7):e206371. https://doi.org/10.1172/JCI206371
After publication of their article, the authors noticed that the labels “KP–/–C” and “KP–/–CPb–/–” in Figure 4H were inadvertently switched. The corrected figure panel is shown below. The HTML and PDF versions of the paper have been updated.
The authors regret the error.